Detection of bladder cancer in males
OwnerStephen Peter Fitzgerald, Mark Ruddock +1inventors
InventorsStephen Peter Fitzgerald, Mark Ruddock, John Lamont
Life of this patent
Estimating the term…
Abstract
Haematuria is a considerable burden within primary and secondary care; too many haematuria patients are referred to secondary care for invasive and expensive investigations that could be managed in primary care. The current invention has identified biomarker combinations with utility for the diagnosis of bladder cancer in males. Using gender specific biomarker algorithms in combination with clinical risks that are associated with bladder cancer, would allow clinicians to better manage haematuria patients in primary care setting.
Claims16
A method for the detection of, or determining the risk of, bladder cancer in a male patient comprising the steps of:
- (i) determining the level of a panel of biomarkers in a sample previously isolated from a male patient, said panel of biomarkers comprising one or both of prolactin and LIM And SH3 Protein 1 (LASP-1) and one or more additional biomarker selected from neuron specific enolase (NSE), Plasminogen Activator Inhibitor 1/Tissue Plasminogen Activator complex (PAI-1/tPA), Matrix Metalloprotein 9/Tissue Inhibitor of Metalloprotein 1 complex (MMP-9/TIMP-1), Neutrophil Gelatinase Associated Lipocalin Complex (NGAL), Midkine, Albumin:
- creatinine ratio (ACR), bladder tumour antigen (BTA), cluster of differentiation 44 (CD44), carcinoembryonic antigen (CEA), cytokeratin 18 (CK-18), cytokeratin 20 (CK-20), Clusterin, Creatinine, C reactive protein (CRP), C-X-C motif chemokine ligand 1 (CXCL1), C-X-C Motif Chemokine Ligand 16 (CXCL16), Cystatin B, Cystatin C, D-dimer, epidermal growth factor (EGF), fatty acid-binding protein A (FABP-A), FAS protein (FAS), interferon gamma (IFNγ), interleukin 1α (IL-1α), interleukin 2 receptor alpha chain (IL-2Ra), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin-10 (IL-10), monocyte chemotactic protein 1 (MCP-1), Microalbumin, Matrix Metalloprotein-9/Neutrophil Gelatinase-Associated Lipocalin Complex (MMP-9/NGAL), Osmolality, Progranulin, total urinary Protein, free prostate-specific antigen to total prostate specific antigen ratio (PSA_TPSA), Protein S100-A4 (S100A4), Transforming growth factor beta 1 (TGFβ1), Tumour necrosis factor alpha (TNFα), soluble tumour necrosis factor receptor 1 (sTNFR1), soluble tumour necrosis factor receptor 2 (STNFR2), Tissue Type Plasminogen Activator (TPA), Vascular Endothelial Growth Factor (VEGF) and cholesterol;
- (ii) assessing the presence or risk of bladder cancer in the male patient wherein detection of an altered level of the biomarkers compared to a normal control indicates the presence or the risk of cancer in the male patient from whom the sample is isolated.
A solid support material comprising binding molecules attached thereto, said binding molecules having affinity specific for prolactin with the binding molecules being in discrete locations on the support material.
A method for the detection of, or determining the risk of, bladder cancer in a male patient comprising the steps of:
- (i) determining that a male patient does not have an infection;
- (ii) detecting the presence of a panel of biomarkers in a sample previously isolated from the male patient, said panel of biomarkers comprising Prolactin or LASP-1, and one or more biomarkers selected from NSE, PAI-1/tPA, Midkine, NGAL, CXCL16 and MMP-9/TIMP-1;
- (iii) assessing the presence or risk of bladder cancer in the male patient wherein detection of an altered level of the biomarkers compared to a normal control indicates the presence or the risk of cancer in the male patient from whom the sample is isolated.
Dependencies are inferred from the claim text.